Journals / Klinik Psikiyatri Dergisi / 2020 / Cilt: 23 - Sayı: 2

Atomoxetine associated red ear: A case report

Atomoksetin ilişkili kırmızı kulak: Olgu sunumu

Pages
232–235
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To our best knowledge this is the first red ear case associated with atomoxetinein literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Red ear syndrome is defined as mostly unilateral burningpain and redness of external ear.
📊
Key Findings & Data:Our patientwas a 10 year old boy diagnosed with attention deficithyperactivity disorder (ADHD) and spesific learning disorder.
💡
Conclusion & Impact:To our best knowledge this is the first red ear case associated with atomoxetinein literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Red ear syndrome is defined as mostly unilateral burningpain and redness of external ear. It has two forms idiopathic and secondary. Idiopathic red ear syndrome ismostly seen in young people and associated withmigraine. Secondary red ear syndrome is more frequentin adults and releated with cervical disorder. Our patientwas a 10 year old boy diagnosed with attention deficithyperactivity disorder (ADHD) and spesific learning disorder. He had a complaint of redness in his ear, followingthe atomoxetine treatment for ADHD. The redness wasappearing after taking atomoxetine in 1 hour. The redness in his ear was unilateral and lasted in 4 hours.Sometimes headaches were accompanied with red ear.After atomoxetine treatment was ceased the rednessand the headache in his ear were dissappered. In thepathophysiology of red ear sydrome there is a disregulation of sympathic outflow. Atomoxetine has a highselectivity for noradrenergic receptors and also has aneffect on periferic noradrenergic receptors. Atomoxetinecould change the sympathic vasodilation/vasoconstruction balance and cause red ear. Although the red ear isnot a life threating situation, it could cause discomfortand anxiety, so the clinicians should keep in mind red earsyndrome while using atomoxetine. To our best knowledge this is the first red ear case associated with atomoxetinein literature.

Özet

Kırmızı kulak sendromu çoğunlukla tek taraflı yanıcı ağrı ve dış kulağın kızarıklığı ile giden bir durumdur. İdiopatik ve ikincil olmak üzere iki formu vardır. İdiopatik kırmızı kulak sendromu daha çok gençlerde ve migren ile ilişkili olarak, erişkinlerde ise servikal bozukluklarla ile ilgili olabilir. Bu olgu sunumunda dikkat eksikliği hiperaktivite bozukluğu ( DEHB) ve özgül öğrenme güçlüğü tanıları bulunan bir 10 yaşında bir erkek hasta sunmaktayız. Hastaya DEHB tedavisine yönelik olarak atomoksetin başlandıktan sonra hastada kulağında kzıarıklık yakınması başladı. Kızarıklık atomoksetin alımını takiben bir saat içinde oluyordu. Kulağındaki kızarıklık tek taraflı oluyor ve 4 saat içinde kayboluyordu. Bazen kızarıklığa başağrısının da eşlik ettiğini belirtiyordu. Atomoksetin kesildikten sonra hastanın kulağındaki kızarıklık ve başağrısı kayboldu. Kırmızı kulağın patofizyolojisinde sempatik desarj disregülesyonu bulunmaktadır.Atomoksetin noradrenerjik reseptörlere karşı yüksek seçiciliği bulunan ve periferik noradrenerjik reseptörler üzerine de etkisi olan bir moleküldür. Atomoksetin sempatik vazodilatasyon / vazokonstrüksiyon dengesini bozarak kırmızı kulağa sebebp olabilir. Atomoksetin ilişkili kırmızı kulak hayatı tehdit edici bir druum olmamakla birlikte rahatsızlık ve kaygıya sebep olabilir. Bu sebeple klinisyenler atomoksetin kullanırken bu durumu akıllarında tutmalıdırlar. Bu olgu sunumu literatürdebulunan ilk atomoksetin ilişkili kırmızı kulak vakasıdır.

🔖

Cite This Article

TANER, H. A., SARI, B. A. (2022). Atomoxetine associated red ear: A case report. Klinik Psikiyatri Dergisi, Cilt: 23 - Sayı: 2, 232–235. https://ajindex.com/articles/573836

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet [Internet]. 2016;387(10024):1240–50
  2. Garnock-Jones KP, Keating GM. Atomoxetine. Pediatr Drugs. 2009;11:203–26
  3. Lambru G, Miller S, Matharu MS. The red ear syndrome. J Headache Pain. 2013;14:83
  4. Ryan S, Wakerley BR, Davies P. Red ear syndrome: a review of all published cases (1996–2010). Cephalalgia. 2013;33:190– 201
  5. Wollina U. Three orphans one should know: red scalp, red ear and red scrotum syndrome. J Eur Acad Dermatology Venereol. 2016;11:e169–70
  6. Gökçen C, Kutuk MO, Coşkun Ş. Dose-Dependent Raynaud’s Phenomenon Developing from Use of Atomoxetine in a Girl. J Child Adolesc Psychopharmacol. 2013;23:428–30
  7. Gülle ZN, Karayagmurlu A, Coskun M. Raynaud’s Phenomenon Related with Atomoxetine Treatment in a Child with Autism and Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2019 Published Online:2 Jul 2019
  8. Eli Lilly and Company.Highlights of Prescribing Information. p. 1–18. https://pi.lilly.com/us/strattera-pi.pdf Accessed on: July 24, 2019 9. Lance JW. The mystery of one red ear. Clin Exp Neurol. 1994;31:13–8
  9. Raieli V, Compagno A, Brighina F, Franca G La, Puma D, Ragusa D, et al. Prevalence of red ear syndrome in juvenile primary headaches. Cephalalgia. 2011;31:597–602
  10. The Uppsala Monitoring Centre. The use of the WHOUMC system for standardised casecausalityassesment.http://www.who.int/medicines/areas/qua lity_safety/safety_efficacy/WHOcausality_assessment.pdf Accessed on: July 24, 2019 12. Kumar N, Swanson JW. The ‘red ear syndrome’revisited: two cases and a review of literature. Cephalalgia. 2004;24:305–8
  11. Flicinski J, Wigowska-Sowinska J, Winczewska-Wiktor A, Steinborn B. Red ear syndrome–Case report and review of literature. Neurol Neurochir Pol. 2015;49:74–7
  12. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699
  13. Mirbolooki MR, Upadhyay SK, Constantinescu CC, Pan ML, Mukherjee J. Adrenergic pathway activation enhances brown adipose tissue metabolism: A [18 F] FDG PET/CT study in mice. Nucl Med Biol. 2014;41:10–6
  14. Bilgiç Ö, Bilgiç A. Possible atomoxetine-induced vitiligo: a case report. ADHD Atten Deficit Hyperact Di